Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 Combined With Proton Craniospinal Irradiation for Leptomeningeal Disease
NCT07814352Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SX-682 in leptomeningeal disease (LMD), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Incidence, severity, and type of adverse event at 3 years. Started Sep 2026; status: recruiting.
02
Drugs
SX-682
03
Conditions
leptomeningeal disease (LMD)
Beyond the preview
Go deeper on NCT07814352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814352.